OOIR: Observatory of International Research

Papers

(The H4-Index of JHEP Reports is 37. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Increased carbohydrate deficient transferrin: Whisky or candy?	194
Reply to: “Hepatic bile acid transport increases in the postprandial state: A functional 11C-CSar PET/CT study in healthy humans”	137
Changing epidemiology of hepatocellular carcinoma in the Mediterranean area: A challenge for surveillance?	126
The weight of choices: Prioritizing lifestyle over GLP-1 receptor agonist therapy in managing MASLD	107
Copyright and information	78
Heterogeneity in intrahepatic macrophage populations and druggable target expression in patients with steatotic liver disease-related fibrosis	76
Combined inhibition of bile salt synthesis and intestinal uptake reduces cholestatic liver damage and colonic bile salts in mice	67
Inevitability of disease recurrence after liver transplantation for NAFLD cirrhosis	66
Predicting liver ablation volumes with real-time MRI thermometry	65
Lower pretreatment HBV DNA levels are associated with better off-treatment outcomes after nucleo(s)tide analogue withdrawal in patients with HBeAg-negative chronic hepatitis B: A multicentre cohort st	62
What to do about hepatocellular carcinoma: Recommendations for health authorities from the International Liver Cancer Association	62
A small animal model of chronic hepatitis E infection using immunocompromised rats	62
Time for a globally unified chronic HBV terminology?	56
AFP score and metroticket 2.0 perform similarly and could be used in a “within-ALL” clinical decision tool	54
Emerging roles of circular RNAs in liver cancer	54
Reply to: “Dynamic imaging of macrophages in MASLD: A major interest in insulin resistance and outside the liver”	51
Protective role of physical activity against HCC risk in type 2 diabetes: Evidence and public health perspectives	51
Erratum to “Opinion paper on the diagnosis and treatment of progressive familial intrahepatic cholestasis” [JHEP Reports 6 (2024) 100949]	48
Copyright and information	48
Liver stiffness measurement predicts clinical outcomes in autoimmune hepatitis	47
Development and validation of circulating protein signatures as diagnostic biomarkers for biliary tract cancer	46
Mapping the hemodynamic effects of terlipressin in patients with hepatorenal syndrome using advanced magnetic resonance imaging	46
Induction of phospholipase A2 group 4C by HCV infection regulates lipid droplet formation	45
Comparative Effectiveness of Antidiabetic Therapies on Hepatic Decompensation in Patients with Type 2 Diabetes: A Target Trial Emulation	43
Human umbilical cord mesenchymal stem cell-derived exosomes ameliorate liver steatosis by promoting fatty acid oxidation and reducing fatty acid synthesis	43

HCV microelimination in harm reduction centres has benefits beyond HCV cure but is hampered by high reinfection rates	43
External validation of the IAIHG autoimmune hepatitis response criteria in a multicentric real-world cohort	42
Hepatitis C virus replication requires integrity of mitochondria-associated ER membranes	41
Statistical precision of p values: a note on “Liver fibrosis progression analyzed with AI predicts renal decline”	41
MELD 3.i: A Bayesian framework for updating the model for end-stage liver disease score	41
Identifying emergency presentations of chronic liver disease using routinely collected administrative hospital data	41
Epigenetics of alcohol-related liver diseases	40
Editorial Board page	38
JMJD2D stabilises and cooperates with HBx protein to promote HBV transcription and replication	38
Dynamic evolution of the sofosbuvir-associated variant A1343V in HEV-infected patients under concomitant sofosbuvir-ribavirin treatment	37
Editorial Board page	37
Copyright and information	37